EMERYVILLE, Calif., October 25, 2022 /PRNewswire/ — Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company accelerating the global transition to sustainable consumption through its Lab-to-Market™ technology platform and consumer brands of products of clean beauty, today announced a partnership with World Wildlife Fund (WWF), one of the world’s leading conservation organizations, to support WWF’s efforts to improve ocean health and reduce the impact of fishing on shark populations.
The partnership underscores and reinforces Amyris’ ESG commitment, as outlined in the company’s recently announced report 2021 Environmental, Social and Governance (“ESG”) Report. According to the most recent Living Planet Report in 2022, population sizes of mammals, birds, fish, amphibians and reptiles have experienced an alarming average decline of 69% since 1970. This loss affects human health and well-being, which is why WWF and Amyris join forces to support and protect biodiversity.
During the first year of this partnership, Amyris will support WWF: (1) to stimulate fishing in Ecuador and Peru to more sustainable fishing and (2) to reduce the impacts of fishing gear on sharks. In addition, Amyris and WWF will collaborate to identify target ingredients from Amyris’ molecule pipeline that could reduce impact on ocean ecosystems and have a significant impact on biodiversity and threatened habitats.
“We are delighted to partner with WWF to continue and deepen our commitment to protecting biodiversity,” said Beth Bannerman, Director of Engagement and Sustainable Development, Amyris. “Every day at Amyris, we think about how we can improve the health of people and the planet, push boundaries and drive change, and this partnership is a natural fit.”
“As our planet faces a biodiversity crisis, the need for businesses to invest in solutions that protect the health of critical habitats, including our oceans, has never been greater,” said Sheila Bonini, SVP Private Sector Engagement, World Wide Fund for Nature. “We are excited about the opportunities this partnership offers to show the positive link between sustainability, clean chemistry and healthy habitats and the importance of science leading to positive impacts on biodiversity.
Amyris (Nasdaq: AMRS) is a leading synthetic biotechnology company, transitioning the clean health and beauty and flavors and fragrances markets to sustainable ingredients through fermentation and the technology platform the company’s exclusive Lab-to-Market™. This Amyris platform leverages state-of-the-art machine learning, robotics and artificial intelligence, enabling the company to quickly bring new innovations to market at commercial scale. Amyris ingredients are included in more than 20,000 products from the world’s leading brands, reaching more than 300 million consumers. Amyris also owns and operates a family of consumer brands that are constantly evolving to meet the growing demand for durable, efficient and accessible products. For more information, please visit http://www.amyris.com.
Amyris, the Amyris logo, and Lab-to-Market are trademarks or registered trademarks of Amyris, Inc. or its subsidiaries in the United States and/or other countries.
This press release contains forward-looking statements, and any statements other than statements of historical fact may be deemed to be forward-looking statements. These forward-looking statements include, among other things, statements regarding future events, such as Amyris’ commitment to clean and sustainable chemistry consistent with its ESG goals and priorities and Amyris’ expectations as to how its partnership with the WWF could have an impact on ocean ecosystems and protect biodiversity. These statements are based on management’s current expectations and actual results and future events may differ materially due to risks and uncertainties, including risks relating to Amyris’ liquidity and ability to fund capital expenditures. operating and investing activities, risks relating to its financing activities, risks relating to potential delays or failures in the completion and integration of planned acquisitions, risks relating to potential delays or failures in the development, regulatory approval, the launch, production and commercialization of products, risks related to the COVID-19 pandemic and any other geopolitical event, including Russia invasion of Ukraine, resulting in global economic, financial and supply chain disruptions that may adversely impact Amyris’ business operations and financial results or result in market volatility, risks related to dependence on Amyris to third parties, particularly in the supply chain, and other risks detailed from time to time in Amyris’ filings with the Securities and Exchange Commission, including annual reports on Form 10- K, quarterly reports on Form 10-Q and current reports on Form 8-K. Amyris assumes no obligation to update the information contained in these forward-looking statements, whether as a result of new information, future events or otherwise.